Anti-Estrogen Therapy for Inguinal Hernia

(RIGHT Trial)

This trial tests anti-estrogen treatments to determine their effectiveness for men with inguinal hernias, a condition where part of the intestine pushes through the abdominal wall. Researchers will evaluate two drugs, fulvestrant and letrozole, to assess their safety and effectiveness over six months. Men aged 50 or older with a single, symptomatic inguinal hernia confirmed by ultrasound may qualify for this study. The trial will monitor changes in hormone levels, hernia size, and patient experiences. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive these treatments.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Previous studies have safely used fulvestrant in humans for various conditions. The FDA has approved it for treating certain types of breast cancer, indicating a well-understood safety profile. Some reports mention mild reactions at the injection site and nausea.

Research has shown letrozole to be a safe treatment for breast cancer in women. However, it may reduce bone strength, so monitoring bone health is recommended.

Researchers are excited about using anti-estrogen treatments like fulvestrant and letrozole for inguinal hernias because they offer a novel approach compared to traditional surgical options. Fulvestrant, typically used in breast cancer, works by blocking estrogen receptors, potentially reducing inflammation and tissue growth linked to hernias. Letrozole, an aromatase inhibitor, lowers estrogen levels in the body, which might help in managing hernia symptoms differently than current surgical methods. These treatments could provide non-surgical alternatives, offering fewer risks and recovery challenges for patients.

Research has shown that treatments blocking estrogen, such as fulvestrant and letrozole, might help manage inguinal hernias. In this trial, participants will receive either fulvestrant or letrozole. In mouse studies, fulvestrant shrank large hernias and reversed muscle damage, suggesting it might also reduce hernias in people. Letrozole, which stops estrogen production, prevented inguinal hernias in similar animal studies. Researchers are examining both treatments for their potential to manage hernias without surgery by altering hormone levels. Early results are promising, but further research is needed to confirm these effects in humans.¹²⁵⁶⁷